Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

  • Moorthy V
  • McConkey S
  • Roberts M
 et al. 
  • 32


    Mendeley users who have this article in their library.
  • 74


    Citations of this article.


A series of phase I clinical studies were conducted to evaluate the safety of plasmid DNA and modified vaccinia virus Ankara malaria vaccines. The vaccines each encoded a polyepitope string fused to whole Plasmodium falciparum TRAP antigen. Forty-three healthy adult volunteers received the vaccines alone or in DNA/MVA prime-boost combinations. The DNA vaccine was administered either intramuscularly by needle or intradermally by a needleless delivery device. The MVA vaccine was administered intradermally by needle. The vaccines were well-tolerated by all three routes and in various DNA/MVA immunisation regimes. There were no severe or serious adverse events. © 2002 Elsevier Science Ltd. All rights reserved.

Author-supplied keywords

  • Malaria
  • Safety
  • Vaccine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • V. S. Moorthy

  • S. McConkey

  • M. Roberts

  • P. Gothard

  • N. Arulanantham

  • P. Degano

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free